Objetivo
The world is facing an antibiotics crisis, with resistant bacteria rendering current treatments ineffective. Novel, effective solutions are urgently required for this $40bn global market. Westway Health (WWH) is based in Galway, Ireland, and is on track to become a leading veterinary antimicrobials company in the EU. It has developed an innovative, non-antibiotic technology, effective at killing all bacteria, including antibiotic-resistant bacteria like MRSA, while not inducing resistance. WWH’s lead product in development is PanaMastTM LC, a breakthrough treatment of bovine mastitis, the most economically important infectious disease affecting the dairy industry. PanaMastTM LC will represent a step change in the way that dairy farmers manage mastitis, which affects 30% of the herd annually. It will: 1. Be the world’s first non-antibiotic medicine for mastitis, offering superior clinical outcomes and significant financial gains to end-users (€150/case); 2. Reduce wastage of milk and culling of cows; (3) Improve profitability and environmental performance on European farms and dairy processing sites. The innovation directly addresses the major global problem of antibiotic resistance, while providing a sustainable animal health solution that supports production of safe and high quality food. The Phase 1 PanaMast project was successfully completed ahead of schedule and on budget. It allowed WWH to: 1. Develop a regulatory roadmap detailing all steps required to progress from current stage of development (TRL7) to first sale of commercial product (TRL8); 2. Develop a robust commercial exploitation plan for PanaMastTM LC in EU and global markets; 3. Establish key strategic relationships to assist commercialisation of PanaMastTM LC
The Phase 1 results underpin this proposed project. The Phase 2 activities (pre-commercialisation/product development/product launch and commercialisation) are designed to ensure market launch and sale of PanaMastTM LC in the EU at TRL8 by 2020
Ámbito científico
- medical and health scienceshealth sciencespublic health
- natural sciencesbiological sciencesmicrobiologybacteriology
- agricultural sciencesanimal and dairy sciencedairy
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programa(s)
- H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy Main Programme
- H2020-EU.3.2.4. - Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy
- H2020-EU.3.2.1. - Sustainable agriculture and forestry
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
- H2020-EU.3.2.2. - Sustainable and competitive agri-food sector for a safe and healthy diet
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEINST-2-2016-2017
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
H91 Galway
Irlanda
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.